Section Arrow
LYEL.NASDAQ
- Lyell Immunopharma Inc
Quotes are at least 15-min delayed:2026/10/20 23:10 EDT
Regular Hours
Last
 9.7
+0.9 (+10.23%)
Day High 
10.01 
Prev. Close
8.8 
1-M High
11.225 
Volume 
158.62K 
Bid
9
Ask
14
Day Low
8.565 
Open
8.74 
1-M Low
7.195 
Market Cap 
215.65M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.36 
20-SMA 9.11 
50-SMA 11.84 
52-W High 45 
52-W Low 7.195 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-12.69/-9.76
Enterprise Value
257.57M
Balance Sheet
Book Value Per Share
9.54
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
36.00K
Operating Revenue Per Share
1.98
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EYPTEyePoint Inc.0.4052-0.0348-7.91%-- 
RXRXRecursion Pharmaceuticals3.66+0.05+1.39%-- 
MRNAModerna242.08+15.19+6.69%-- 
IBRXImmunityBio8.77+0.35+4.16%-- 
SLNSilence Therapeutics Plc19.61+0.03+0.15%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) andother GCC-expressing cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.